ALTEOGEN INC.AA

ALTEOGEN INC.

368,500KRWD
−12,500−3.28%
At close at Jun 5, 07:52 GMT
KRW
No trades
See on Supercharts

196170 fundamentals

Key facts

Market capitalization‪19.70 T‬KRW
Basic EPS (TTM)2,334.57KRW
Founded2008
CEOSun-Jae Park
About

Alteogen, Inc. engages in the development, manufacture, and sale of biopharmaceuticals and anticancer drugs. Its products include technologies for anti-breast cancer drug and biosimilar, technology consulting, and other services. The company was founded on May 13, 2008 and is headquartered in Daejeon, South Korea.

Ownership
‪‪53.44 M‬‬
Free Float shares
‪‪39.22 M‬‬ (73.38%)
Closely held shares
‪‪14.23 M‬‬ (26.62%)
Free Float shares
‪‪39.22 M‬‬ (73.38%)
Closely held shares
‪‪14.23 M‬‬ (26.62%)
Capital structure
Market cap
‪‪19.70 T‬‬
Debt
‪‪127.16 B‬‬
Minority interest
‪‪6.26 B‬‬
Cash & equivalents
‪‪329.80 B‬‬
Enterprise value
‪‪19.50 T‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪19.70 T‬‬
Price to earning ratio (P/E)
163.74x
Price to sales ratio (P/S)
134.56x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
163.74x
Price to sales ratio (P/S)
134.56x
Valuation ratios
‪0.00‬
‪60.00‬
‪120.00‬
‪180.00‬
‪240.00‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪110.00‬
‪220.00‬
‪330.00‬
‪440.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−200%‬
‪−100%‬
‪0%‬
‪100%‬
‪200%‬
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−30.00 B‬‬
‪0.00‬
‪‪30.00 B‬‬
‪‪60.00 B‬‬
‪‪90.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪21.00 B‬‬
‪‪42.00 B‬‬
‪‪63.00 B‬‬
‪‪84.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪21.00 B‬‬
‪‪42.00 B‬‬
‪‪63.00 B‬‬
‪‪84.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Research Service
Genetic Development and Development of Transgenic Plants and Animals
Merchandise
By country
Period: 2024
Overseas
South Korea

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪11.00 B‬‬
‪‪22.00 B‬‬
‪‪33.00 B‬‬
‪‪44.00 B‬‬
Actual
Estimate
Earnings
Next:Mar 23, 2026
2021
2022
2023
2024
2025
‪−900.00‬
‪0.00‬
‪900.00‬
‪‪1.80 K‬‬
‪‪2.70 K‬‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

No dividends
196170 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪‪−45.00 B‬‬
‪0.00‬
‪‪45.00 B‬‬
‪‪90.00 B‬‬
‪‪135.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪110.00 B‬‬
‪‪220.00 B‬‬
‪‪330.00 B‬‬
‪‪440.00 B‬‬
Assets
Liabilities